We’re delighted to announce a genetic analysis project supported by Msingi East Africa. This project helps to enable modern genetic selective breeding in tilapia operations in Kenya and Uganda.
The project is a significant step forward in sustainable aquaculture in the area, and began with our experts providing the partner farms with on-the-ground training in the best methods to take tissue samples. The samples were then brought back to Xelect’s custom built laboratory in Scotland for DNA extraction and genetic analysis. This data will help East African Tilapia producers be used to create long-term, sustainable breeding programme plans.
Our Operations Director, Dr Tom Ashton, who recently returned from a follow up visit in Kenya, commented: “We’re delighted to be working with East African tilapia hatcheries. Despite occasional interruptions from a hippo and monitor lizards we’re now a major step closer to helping with regional food stability for the area”.
2020 has already been a period of considerable expansion for us, as we have secured 6 new partnerships in recent months. We also recently announced an expansion of our breeding programme management team, a new rapid response genetics service and have made a number of key hires in genetics and marketing.
Our CEO Professor Ian Johnston believes this growth is due to an increasing maturity in the market. “With so much inward investment in the industry we’ve reached a tipping point. We believe the market will ultimately fracture into major producers, using the latest genetics best practice, and smaller local operations. Investors would be very unwise to commit significant resources to aquaculture operations if they don’t truly understand and protect the genetic capital of their broodstock.”
Xelect Introducers – Our new partnerships programme
Xelect announce new partnership in Kenya: Unlocking the genetic potential of tilapia
Genetics and RAS: does the new frontier in global aquaculture require a fresh approach to selective breeding?
Xelect welcomes new talent in the lab
COVID-19 and the ‘new normal’